£810 / $1295 / €985
Online, PDF
We expect the Venezuelan government to continue its foreign currency and import control policies in Q412 and the local market will endure further government restrictions on pharmaceutical and healthcare industry. Multinationals will have the potential revenue-generation opportunities from Venezuela's increasing reliance on imported products to meet local demand, as the election outcome will not fix the production capacity issues in the domestic industry.
Headline Expenditure Projections
Pharmaceuticals : VEB33.26bn (US$5.46bn) in 2011 to VEB40.77bn (US$6.00bn) in 2012; +22.6% in local currency terms and +10.0% in US dollar terms. Forecasts down due to new industrial information.
Healthcare: VEB66.69bn (US$10.94bn) in 2011 to VEB83.29bn (US$12.26bn) in 2012; +24.9% in local currency terms and +12.0% in US dollar terms. Forecasts up due to new macro data.
Medical devices: VEB9.62bn (US$1.58bn) in 2011 to VEB11.54bn (US$1.70bn) in 2012; +20.0% in local currency terms and 7.6% in US dollar terms. Forecasts down due to new macroeconomic data.
Competitive Landscape
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.